All In Biotech

Drug Trial Radar · NCT07598318

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

A Randomized, Controlled, Open-Label, Multi-center Study of Becotatug Vedotin (EGFR-ADC) Combined With Chemo and Immunotherapy vs. Chemo and Immunotherapy as First-Line Treatment in Advanced/Metastatic EGFR-Mutated Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Sir Run Run Shaw HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or metastatic biliary tract cancer whose tumors carry EGFR mutations. Participants will be randomly assigned to receive either the experimental combination (becotatug vedotin + pucotenlimab + gemcitabine + cisplatin) or the control combination (pucotenlimab + gemcitabine + cisplatin). The main goal is to see if the experimental group has a higher objective response rate (tumor shrinkage rate). This is a randomized, controlled, open-label, multicenter study led by Sir Run Run Shaw Hospital, Zhejiang University, with Dr. Chen Mingyu as the principal investigator.

Conditions

  • Cholangiocarcinoma

Interventions

  • Becotatug VedotinDrug

    Becotatug Vedotin:2mg/kg,IV,Q3W,D1

  • PucotenlimabDrug

    Pucotenlimab:200mg,IV,Q3W,D1

  • GemcitabineDrug

    Gemcitabine:1000mg/m²,IV,D1、D8,Q3W. Each course lasts for 8 weeks. The maximum treatment duration is 8 courses.

  • CisplatinDrug

    Cisplatin:25mg/m²,IV,D1、D8,Q3W. Each course lasts for 8 weeks. The maximum treatment duration is 8 courses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: After two treatment cycles(each cycle is 28 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.